Akebia Therapeutics (AKBA) Assets Average: 2016-2025
Historic Assets Average for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $354.9 million.
- Akebia Therapeutics' Assets Average rose 66.09% to $354.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $354.9 million, marking a year-over-year increase of 66.09%. This contributed to the annual value of $231.2 million for FY2024, which is 22.65% down from last year.
- As of Q3 2025, Akebia Therapeutics' Assets Average stood at $354.9 million, which was up 8.23% from $327.9 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Assets Average peaked at $636.4 million during Q1 2021, and registered a low of $213.7 million during Q3 2024.
- In the last 3 years, Akebia Therapeutics' Assets Average had a median value of $244.4 million in 2023 and averaged $263.7 million.
- In the last 5 years, Akebia Therapeutics' Assets Average tumbled by 50.11% in 2023 and then soared by 66.09% in 2025.
- Akebia Therapeutics' Assets Average (Quarterly) stood at $565.8 million in 2021, then declined by 29.28% to $400.2 million in 2022, then crashed by 40.44% to $238.4 million in 2023, then decreased by 10.26% to $213.9 million in 2024, then surged by 66.09% to $354.9 million in 2025.
- Its last three reported values are $354.9 million in Q3 2025, $327.9 million for Q2 2025, and $265.4 million during Q1 2025.